ProPhase Labs Inkomsten in het verleden
Verleden criteriumcontroles 0/6
ProPhase Labs's earnings have been declining at an average annual rate of -14.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 27.4% per year.
Belangrijke informatie
-14.7%
Groei van de winst
-8.4%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 6.0% |
Inkomstengroei | 27.4% |
Rendement op eigen vermogen | -59.7% |
Nettomarge | -146.4% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower
Jul 03Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12Opbrengsten en kosten
Hoe ProPhase Labs geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 18 | -26 | 31 | 1 |
31 Mar 24 | 29 | -24 | 34 | 2 |
31 Dec 23 | 44 | -17 | 35 | 3 |
30 Sep 23 | 63 | -10 | 39 | 7 |
30 Jun 23 | 79 | -4 | 38 | 9 |
31 Mar 23 | 94 | 7 | 35 | 9 |
31 Dec 22 | 123 | 18 | 34 | 13 |
30 Sep 22 | 146 | 31 | 29 | 12 |
30 Jun 22 | 131 | 27 | 28 | 11 |
31 Mar 22 | 111 | 18 | 27 | 10 |
31 Dec 21 | 79 | 6 | 22 | 10 |
30 Sep 21 | 39 | -5 | 18 | 7 |
30 Jun 21 | 33 | -2 | 14 | 6 |
31 Mar 21 | 28 | 0 | 10 | 5 |
31 Dec 20 | 15 | -2 | 7 | 1 |
30 Sep 20 | 12 | -2 | 5 | 0 |
30 Jun 20 | 11 | -2 | 5 | 0 |
31 Mar 20 | 9 | -3 | 5 | 0 |
31 Dec 19 | 10 | -3 | 6 | 0 |
30 Sep 19 | 11 | -3 | 6 | 0 |
30 Jun 19 | 11 | -4 | 6 | 0 |
31 Mar 19 | 12 | -3 | 6 | 0 |
31 Dec 18 | 13 | -2 | 6 | 0 |
30 Sep 18 | 13 | -1 | 6 | 0 |
30 Jun 18 | 14 | -1 | 6 | 0 |
31 Mar 18 | 13 | -1 | 6 | 0 |
31 Dec 17 | 10 | -2 | 6 | 0 |
30 Sep 17 | 6 | -3 | 5 | 0 |
30 Jun 17 | 5 | -3 | 4 | 0 |
31 Mar 17 | 4 | -3 | 4 | 0 |
31 Dec 16 | 4 | -4 | 4 | 0 |
30 Sep 16 | -6 | -3 | -3 | 0 |
30 Jun 16 | -3 | -2 | -2 | 0 |
31 Mar 16 | -2 | -2 | -1 | 0 |
31 Dec 15 | 3 | -2 | 3 | 0 |
30 Sep 15 | 21 | -3 | 15 | 1 |
30 Jun 15 | 22 | -7 | 16 | 1 |
31 Mar 15 | 22 | -8 | 17 | 1 |
31 Dec 14 | 22 | -8 | 17 | 1 |
30 Sep 14 | 23 | -7 | 17 | 1 |
30 Jun 14 | 24 | -2 | 16 | 1 |
31 Mar 14 | 24 | -1 | 15 | 1 |
31 Dec 13 | 25 | 0 | 15 | 1 |
Kwaliteitswinsten: PRPH is currently unprofitable.
Groeiende winstmarge: PRPH is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PRPH is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Versnelling van de groei: Unable to compare PRPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: PRPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: PRPH has a negative Return on Equity (-59.69%), as it is currently unprofitable.